CONTINUING LEGAL EDUCATION CREDIT SELF REPORTING ATTENDANCE AND EVALUATION FORM — TWENTY-THIRD PHARMACEUTICAL AND MEDICAL DEVICE ETHICS AND COMPLIANCE CONGRESS

The Pharma Congress is an approved Distance Learning Provider for PA MCLE. As such, the Congress will submit and pay for claimed CLE credits to PA MCLE for attorneys barred in Pennsylvania. For attorneys barred in other states, the Summit will post a record of their attendance at the Pharma Congress in the PA MCLE databases and will issue an Pharma Congress Certificate of Attendance that the attorney seeking CLE credits may use to self-report their participation to states. The Pharma Congress does not guarantee that states will accept the Certificate of Attendance.

As a pre-requisite to the submission of claimed CLE credits to PA MCLE for attorneys barred in Pennsylvania and the issuance of a Pharma Congress Certificate of Attendance, a Pharma Congress attorney attendee must:

- Pay a fee of $100 to the Pharma Congress @ **www.pharmacongress.com**, and
- Fully complete and execute this CONTINUING LEGAL EDUCATION CREDIT SELF REPORTING ATTENDANCE AND EVALUATION FORM FOR THE PHARMA CONGRESS. Payment must be made and the completed and executed form submitted via email to **suzanne@vmaglobalevents.com** no later than **November 30, 2022.**

PERSONAL CONTACT INFORMATION

COMPLETE THE FOLLOWING:

NAME

SIGNATURE OF REGISTRANT - REQUIRED

JOB TITLE

STATE WHERE YOU PRACTICE

ADDRESS

CITY/STATE/ZIP

TELEPHONE

E-MAIL

PA BAR NUMBER IF FROM PA

NUMBER OF HOURS YOU PARTICIPATED

SELF REPORTING OF ATTENDANCE AT THE TWENTY-THIRD PHARMA CONGRESS

Please mark those Pharma Congress sessions below that you attended virtually. To claim attendance for any session you must not only have been logged in to that session, but you must also have been fully engaged in watching and participating in the session.

DAY I: MONDAY, OCTOBER 24, 2022

MORNING WORKSHOPS

- ☐ **WORKSHOP 1: Overview of ESG and the Role of Ethics & Compliance** — **1.5 hours**
- ☐ **WORKSHOP 2 : Behavioral Compliance: Overview and Application with Pharma Compliance Leaders** — **1.5 hours**

MINI SUMMITS GROUP I

- ☐ **MINI-SUMMIT 1: Compliance Considerations Intersecting Corporate DE&I Initiatives** — **.75 hour**
- ☐ **MINI-SUMMIT 2 : Compliance and Ethics Considerations for Rare Disease, Genetic Testing** — **.75 hour**
- ☐ **MINI-SUMMIT 3: New Product Launch Compliance Playbook** — **.75 hour**

MINI SUMMITS GROUP II

- ☐ **MINI-SUMMIT 4: You finished your Risk Assessment… Now what? Practical Approaches to Making Your Results Meaningful** — **.75 hour**
- ☐ **MINI-SUMMIT 5 : Social Media — Auditing and Monitoring to Promote Compliance in this Rapidly Evolving Landscape** — **.75 hour**
- ☐ **MINI-SUMMIT 6: Global Considerations for US-Based CCOs** — **.75 hour**

MINI SUMMITS GROUP III

- ☐ **MINI-SUMMIT 7: Current Trends in FMV** — **.75 hour**
- ☐ **MINI-SUMMIT 8 : New and Emerging Risks for Medical Device** — **.75 hour**
- ☐ **MINI-SUMMIT 9: Compliance & Ethics in Emerging Companies** — **.75 hour**
- ☐ **MINI-SUMMIT 10: Compliance Consideration for State Price Transparency** — **.75 hour**

PHARMA CONGRESS DAY I OPENING PLENARY SESSION

- [ ] **Welcome and Introductions** .25 hour
- [ ] **Keynote: US HHS Office of Inspector General Update** 1 hour
- [ ] **US Department of Justice Keynote Fireside Chat** .5 hour
- [ ] **Recent Federal and State Enforcement Activities for the Pharma and Medical Device Industries** 1 hour
- [ ] **Annual Chief Compliance Officer Fireside Chat** 1.25 hours

DAY II: TUESDAY, OCTOBER 25, 2022

MINI SUMMITS GROUP IV

- [ ] MINI-SUMMIT 11: Integrating HCP Engagement Systems .75 hour
- [ ] MINI-SUMMIT 12: Future of TPRM – Challenges and Opportunities .75 hour
- [ ] MINI-SUMMIT 13: Reimbursement & Product Support: Controls and Best Practices .75 hour
- [ ] MINI-SUMMIT 14: General Corporate Compliance in an Early-Stage Company and Shared Learnings for Larger Companies .75 hour
- [ ] MINI-SUMMIT 15: Clinical Trials: The Evolving Landscape of Clinical Trials and Innovative Ways for Tracking and Managing Risks .75 hour

CHIEF COMPLIANCE OFFICER ROUNDTABLE

- [ ] **Welcome, Co-Chair Introductions and Antitrust Admonition** .17 hour
- [ ] **CEOs and CCOs Sign on the Compliance Dotted Line — Now What?** .83 hour
- [ ] **Getting the Board Onboard with Healthcare Compliance** 1 hour
- [ ] **Open Forum: Debrief, Questions and Knowledge Sharing** .5 hour

MINI SUMMITS GROUP V

- [ ] MINI-SUMMIT 16: Compliance Considerations Related to Sanctions .75 hour
- [ ] MINI-SUMMIT 17: Data Analytics Use in Digitizing Compliance .75 hour
- [ ] MINI-SUMMIT 18: The Evolving Transparency Reporting Landscape: Changes in 2022 and Preparing for 2023 .75 hour
- [ ] MINI-SUMMIT 19: Best Practices in Managing Investigations .75 hour
- [ ] MINI-SUMMIT 20: Medical Affairs Today: Managing Evolving Risks .75 hour

MINI SUMMITS GROUP VI

- [ ] MINI-SUMMIT 21: One Year Later — Strategic Considerations Based on Lessons Learned Post Implementation of PhRMA and AdvaMed Updates .75 hour
- [ ] MINI-SUMMIT 22: Navigating Telehealth Compliance Considerations for Pharma Companies .75 hour
- [ ] MINI-SUMMIT 23: Compliance Considerations with Industry Educational Endeavors: Grants, Publications and Scientific Exchange .75 hour
- [ ] MINI-SUMMIT 24: Compliance Considerations in Digital Health Collaborations .75 hour
- [ ] MINI-SUMMIT 25: Compliance Due Diligence in Mergers & Acquisitions .75 hour

MINI SUMMITS GROUP VII

- [ ] MINI-SUMMIT 26: Modern Day Compliance — Thoughtful Risk Taking .75 hour
- [ ] MINI-SUMMIT 27: Developing and Implementing a Risk-Based Monitoring Program .75 hour
- [ ] MINI-SUMMIT 28: Practical Guidance for Building Better Compliance Training .75 hour
- [ ] MINI-SUMMIT 29: Building a Cutting-Edge Compliance Program in the Midst of a CIA .75 hour
- [ ] MINI-SUMMIT 30: Data and the Beast .75 hour

CLOSING PLENARY SESSION

- [ ] **Welcome and Introductions** .25 hour
- [ ] **Pharmaceutical and Medical Device Compliance Updates** .5 hour
- [ ] **FDA Keynote featuring Catherine (Katie) Gray, Acting Director, FDA OPDP** .5 hour
- [ ] **AUSA Roundtable** .75 hour
- [ ] **Day II Recap and Adjournment** .25 hour
- [ ] **Update on Whistleblower Legislation** .75 hour

DAY III: WEDNESDAY, OCTOBER 26, 2022

INDUSTRY ONLY BEST PRACTICES THINK TANK

- ☐ **Welcome, Introduction and Antitrust Admonition** — **.17 hour**
- ☐ **Thinking Like a Scientist: Integrating Behavioral Analytics into Your Compliance Program** — **1.08 hours**
- ☐ **Cardiac Arrest — A CEO Lessons Learned from Surviving a Five-Year Criminal Prosecution** — **.92 hour**
- ☐ **Compliance and Ethics Polling Questions (Breakout Warmup)** — **.17 hour**
- ☐ **Hot Topics Table Breakout Discussions** — **.75 hour**
- ☐ **Debrief, Q&A and Best Practice Sharing** — **.58 hour**

EVALUATION FORM FOR THE PHARMA CONGRESS

You must also complete the following Pharma Congress evaluation form:

	Failed to Meet Expectations	Needs Improvement	Met Expectations	Exceded Expectations	Excellent
Overall Quality	☐	☐	☐	☐	☐
Powerpoints	☐	☐	☐	☐	☐
Speakers	☐	☐	☐	☐	☐
Ease of Use	☐	☐	☐	☐	☐

EXECUTION OF THE CONTINUING LEGAL EDUCATION CREDIT SELF REPORTING ATTENDANCE AND EVALUATION FORM FOR THE PHARMA CONGRESS

By executing this self-reporting form, the attorney hereby warrants that the information provided herein is complete, true and correct.

Executed by: _____ **Date:** _____

Payment must be made and the completed and executed form submitted via email to **suzanne@vmaglobalevents.com** no later than **November 30, 2022.**